Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389697 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL6932666 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL18026267 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL13298724 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL13318313 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL25381577 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL6931270 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL3207006 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL19519647 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL12792418 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2024-09-10 | — | — | US | disclosed |
| EP-3603647-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO LTD (KR) | 2024-08-21 | — | — | EP | disclosed |
| CN-113616659-B | Pharmaceutical composition containing adenosine derivative | 未来制药有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20220143029-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | FUTURE MEDICINE CO., LTD. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-11266650-B2 | Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives | FUTURE MEDICINE CO., LTD. (KR) | 2022-03-08 | — | — | US | disclosed |
| US-20210386771-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO., LTD. (KR) | 2021-12-16 | — | — | US | disclosed |
| US-11185556-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2021-11-30 | — | — | US | disclosed |
| US-20200046711-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | FUTURE MEDICINE CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| EP-3603647-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | Future Medicine Co., Ltd. (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3533452-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | Future Medicine Co., Ltd. (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-9018371-B2 | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient | FM THERAPEUTICS CO., LTD. (KR) | 2015-04-28 | — | — | US | disclosed |
| EP-1551412-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROPHINES | MINERVA PATENTS SA (LU) | 2011-05-04 | — | — | EP | disclosed |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FUTURE MEDICINE CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| US-7625892-B2 | Pharmaceutical compositions for the treatment of diseases related to neurotrophines | MIMETECH S.R.L. (IT) | 2009-12-01 | — | — | US | disclosed |
| US-7625892-B2 | Pharmaceutical compositions for the treatment of diseases related to neurotrophines | MIMETECH S.R.L. (IT) | 2009-12-01 | — | — | US | disclosed |
| EP-0832091-B1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA SICOR INC (US) | 2004-01-14 | — | — | EP | disclosed |
| US-5763596-A | PYROLO PYRIMIDINE AND PYRAZOLO PYRIMIDINE COMPOUMDS; TREATMENT OF CARDIOVASCULAR AND BRAIN DISORDERS, ANTIINFLAMMATORY AGENTS | METABASIS THERAPEUTICS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5674998-A | FOR TREATING CARDIOVASCULAR OR BRAIN DISORDERS, OR AS ANTIINFLAMMATORY AGENT | GENSIA INC. (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185556-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, PDE3A | CA1 3113/4885CA2 161/4885MGAM 2203/4885 |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, ADORA3 | CA1 3088/4885CA2 145/4885MGAM 2289/4885 |
| US-20210386771-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | ADORA1, ADORA2A, ADORA3 | CA1 3088/4885CA2 145/4885MGAM 2289/4885 |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ADORA3, ADORA2A, ADORA1 | CA1 4342/4885CA2 3844/4885MGAM 3507/4885 |
| US-20220143029-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | SLC10A1, LIPC, ADORA1 | CA1 4621/4885CA2 3277/4885MGAM 2857/4885 |
| US-20200046711-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | SLC10A1, ADORA1, LIPC | CA1 4728/4885CA2 3425/4885MGAM 3258/4885 |
| US-11266650-B2 | Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives | SLC10A1, ADORA1, LIPC | CA1 4728/4885CA2 3425/4885MGAM 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.